Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Maternal embryonic leucine zipper kinase (MELK) is a serine/threonine protein kinase involved in cell cycle regulation, stem cell self-renewal, apoptosis, splicing regulation, and gene expression. It plays a role in embryonic development, hematopoiesis, and oncogenesis, with high expression observed in various cancers. Pharmacological inhibition of MELK has shown preclinical efficacy in impairing tumor growth, but recent studies suggest its necessity may be context-dependent. Clinical trials are ongoing for inhibitors targeting MELK.
Inhibition of MELK kinase activity, leading to G2/M arrest and apoptosis in cancer cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Maternal Embryonic Leucine Zipper Kinase (MELK).